Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Galapagos NV Share Price Euronext Bruxelles

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Financials

Sales 2024 * 313M 339M 26.65B Sales 2025 * 302M 328M 25.77B Capitalization 1.66B 1.81B 142B
Net income 2024 * -13M -14.1M -1.11B Net income 2025 * -71M -77M -6.05B EV / Sales 2024 * -5.44 x
Net cash position 2024 * 3.37B 3.65B 287B Net cash position 2025 * 2.97B 3.22B 253B EV / Sales 2025 * -4.33 x
P/E ratio 2024 *
-42.9 x
P/E ratio 2025 *
-16.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.64%
More Fundamentals * Assessed data

Chart Galapagos NV

Dynamic Chart

Latest news about Galapagos NV

Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
Galapagos NV Announces Board Changes CI
Galapagos to Seek Acquisitions CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024 CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding CI
More news

Latest transcript on Galapagos NV

Logo Galapagos NV
Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
More transcripts

Analyst Recommendations on Galapagos NV

Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating MT
Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating MT
RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating MT
More recommendations

Press releases Galapagos NV

Galapagos : Galapagos creates new subscription right plans PU
Galapagos creates new subscription right plans GL
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. GL
Galapagos : Galapagos reports first quarter 2024 financial results PU
Galapagos reports first quarter 2024 financial results   GL
More press releases

News in other languages on Galapagos NV

OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas, Endesa, Tubacex, Sabadell, BBVA, Unicaja, Repsol, Iberdrola, Nvidia, Intel, Richemont, Micron Technology...
AVIS D'ANALYSTES DU JOUR : Scor, Ubisoft, Nvidia, Richemont, Micron Technology...
LE OPINIONI DEGLI ANALISTI DEL GIORNO : Unicredit, Nvidia, Neste, Munich, Tenaris, Iberdrola, Ferrari, Iberdrola, Enel, Dell, Amplifon, Micron Technology...
Galapagos creëert nieuwe inschrijvingsrechtenplannen
Galapagos creëert nieuwe inschrijvingsrechtenplannen
More news

Managers and Directors - Galapagos NV

Managers TitleAgeSince
Paulus Stoffels CEO
 Chief Executive Officer 62 31/03/22
Thad Huston DFI
 Director of Finance/CFO 54 31/05/23
Sandra Cauwenberghs IRC
 Investor Relations Contact - 31/10/20
Members of the board TitleAgeSince
Andrew Dickinson BRD
 Director/Board Member 54 03-26
Jérôme Contamine BRD
 Director/Board Member 66 25/04/22
Simon Sturge BRD
 Director/Board Member 65 18/09/23
More insiders

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Sector
Biotechnology & Medical Research
Calendar
31/07/2024 - Q2 2024 Earnings Release
Related indices
BEL-20
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. GLPG Stock